Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aduro Biotech Receives Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aduro Biotech Receives Milestone

Relates to submission of IND application for ADU-741 in prostate cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aduro Biotech Inc. has received a milestone payment from Janssen Biotech Inc. for Aduro’s submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro’s license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer (mCRPC).

“We are very pleased with our productive partnerships with Janssen,” said Stephen Isaacs, chairman, president and chief executive officer, Aduro. “ADU-741 for prostate cancer is the second LADD-based therapy that Janssen plans to advance into the clinic, in addition to ADU-214 for lung cancer.”

In May 2014, Aduro entered into an agreement granting Janssen an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on Aduro’s novel LADD immunotherapy platform. Under the agreement facilitated by Johnson & Johnson Innovation, Aduro received an upfront payment, milestone payments associated with submission of the IND, and is eligible to receive future development, regulatory and commercialization milestone payments up to a potential total of $346 million as well as royalties on worldwide net sales upon successful launch and commercialization.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters